Evidence map›Paper›PMID 19877742›Full record

ArticleDrugs2009

Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

Pasquale De Bellis

Abstract read
PubMed Publisher
In one paragraph

Article in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Pasquale De BellisUOC Institute of Anesthesia and Resuscitation, Department of Cardiac-Nephrology, Azienda Ospedaliera Universitaria S. Martino di Genova, Genoa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections. Anidulafungin is a well tolerated echinocandin with a favorable pharmacokinetic profile; in particular, its lack of hepatic metabolism and renal excretion enables drug administration without dosage adjustment to subjects with any degree of impaired hepatic or renal function. This simplifies dosing, with a requirement for only once-daily administration and a lack of drug-drug interactions in patients who require multiple medications.

Indexed as

AIDS-Related Opportunistic InfectionsAnidulafunginAntifungal AgentsCandidiasisCross InfectionEchinocandinsHumansAnidulafunginAntifungal AgentsEchinocandins

Identifiers

PMID19877742
OpenAlexW2418155284

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.